Cybin Inc., a clinical-stage neuropsychiatric company, filed its Form 6-K with the United States Securities and Exchange Commission for November 2024, reporting its interim consolidated financial statements for the three and six months ended September 30, 2024. The unaudited financial statements, prepared in accordance with International Accounting Standards, show a net loss of $57.2 million for the quarter and $72.0 million for the six-month period, compared to $11.9 million and $26.4 million for the same periods in 2023, respectively. The company's total assets decreased to $262.4 million from $302.0 million as of March 31, 2024. The report, signed by CEO Doug Drysdale on November 13, 2024, also includes management's discussion and analysis, certifications by the CEO and CFO, and a news release. Cybin's shares are traded on the NYSE American LLC under the symbol 'CYBN'. The company, which focuses on advancing therapies for psychiatric and neurological conditions, has seen an increase in research expenses and share-based compensation during the reported periods.

Cybin Inc., a clinical-stage neuropsychiatric company, filed its Form 6-K with the United States Securities and Exchange Commission for November 2024, reporting its interim consolidated financial statements for the three and six months ended September 30, 2024. The unaudited financial statements, prepared in accordance with International Accounting Standards, show a net loss of $57.2 million for the quarter and $72.0 million for the six-month period, compared to $11.9 million and $26.4 million for the same periods in 2023, respectively. The company's total assets decreased to $262.4 million from $302.0 million as of March 31, 2024. The report, signed by CEO Doug Drysdale on November 13, 2024, also includes management's discussion and analysis, certifications by the CEO and CFO, and a news release. Cybin's shares are traded on the NYSE American LLC under the symbol 'CYBN'. The company, which focuses on advancing therapies for psychiatric and neurological conditions, has seen an increase in research expenses and share-based compensation during the reported periods.